Key facts
- Operator of a pharmaceutical company intended to develop novel therapeutics for the treatment of moderate to severe pain without any side effects.
- Maxona Pharmaceuticals’s last known valuation is $100.9M (Jun 2025).
- It has raised $17.9M across 2 recorded rounds; the latest was Seed Round ($900K) in Jun 2025.
- Maxona Pharmaceuticals has filed 2 Form Ds with the SEC since 2021, most recently Jun 2025 ($900K sold to 15 investors).
- Status: Privately Held (backing).
Free account
See the evidence behind this price
- ·Post-money valuations for all 2 rounds
- ·Watchlist + deal alerts for Maxona Pharmaceuticals
Create free account
No card required
Funding rounds
2 roundsAbout Maxona Pharmaceuticals
Operator of a pharmaceutical company intended to develop novel therapeutics for the treatment of moderate to severe pain without any side effects. The company leverages technology to develop non-opioid, non-NSAID, and non-CBD(cannabidiol ) analgesia using nefopam, a centrally-acting agent exerting anti-nociceptive effects via a triple neurotransmitter mechanism of action, enabling patients to get an opioid-free route of treating pain.
- Sector
- Healthcare
- HQ
- Malvern, PA, United States
- Founded
- 2015
- Employees
- 7
- Website
- maxonapharm.com/
- Ownership
- Privately Held (backing)
PA Mark — not yet priced
Maxona Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.